Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and obesity. It works as a GLP-1 agonist, increasing insulin secretion and improving blood sugar control. By slowing down digestion, semaglutide helps patients feel full and reduces the urge to eat. However, it is currently only approved for individuals with a BMI greater than 30 or those with a BMI greater than 27 and one weight-related comorbidity. At Morph Health and Wellness we are able to treat Patient to a BMI of 19.
The big takeaways:
- Semaglutide is a long-acting injectable medication that is taken once per week.
- It is an effective treatment for type 2 diabetes, reducing blood sugar levels and helping patients achieve a healthy weight.
- The medication works by mimicking the hormone GLP-1, a naturally occurring peptide produced in the gut that controls appetite.
- It stimulates the release of insulin and slows down digestion, helping patients feel full and reducing their urge to eat.
If understanding Semaglutide: A First-Generation GLP-1 Agonist is important; go deeper and learn more about GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication.
Help Center on GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication
A: Common side effects of semaglutide include nausea, diarrhea, vomiting, constipation, and abdominal pain.
A: Studies have shown an average weight loss of about 20% over 72 weeks with Tirzepatide.
A: Early data suggests a potential weight loss of 24% with Retatrutide.
A: Combining peptide therapy with these medications and optimizing testosterone levels can help prevent muscle loss.
A: Injection-based supplementation is recommended for optimizing vitamin D and B12 levels.
